糖尿病之友2023,Issue(3) :15-16,18.

莫沙必利联合雷贝拉唑钠在反流性食管炎患者治疗中的应用

王东华
糖尿病之友2023,Issue(3) :15-16,18.

莫沙必利联合雷贝拉唑钠在反流性食管炎患者治疗中的应用

王东华1
扫码查看

作者信息

  • 1. 惠民县妇幼保健院内科,山东 惠民 251700
  • 折叠

摘要

目的:对反流性食管炎患者采用莫沙必利联合雷贝拉唑钠治疗的效果进行探究。方法:选择我院收治的反流性食管炎患者纳入研究,其划分为对照组和观察组,每组各有60例。对照组接受奥美拉唑联合莫沙必利治疗,观察组则接受雷贝拉唑钠联合莫沙必利治疗。对比两组的治疗效果。结果:与对照组相比,观察组的总有效率明显更高,症状消失时间均明显更短、pH值、LES压力及血清胃泌素水平均明显更高,不良反应发生率明显更低(P均<0.05)。结论:在反流性食管炎患者的治疗中,采用莫沙必利联合雷贝拉唑钠治疗效果确切。

Abstract

Objective:To investigate the effect of mosapride combined with rabeprazole sodium in the treatment of reflux esophagitis.Methods The patients with reflux esophagitis admitted to our hospital were divided into control group and observation group,with 60 cases in each group.The control group received omeprazole combined with mosapride,while the observation group received rabeprazole sodium combined with mosapride.Compare thetreatment effect of the two groups.Results Compared with the control group,the total effective rate of the observation group was significantly higher,the time of symptom disappearance was significantly shorter,the pH value,LES pressure and serum gastrin level were significantly higher,and the incidence of adverse reactions was significantly lower(P<0.05).Conclusion In the treatment of reflux esophagitis,mosapride combined with rabeprazole sodium is effective.

关键词

莫沙必利/雷贝拉唑钠/反流性食管炎

Key words

Mosapride/Rabeprazole sodium/Reflux esophagitis

引用本文复制引用

出版年

2023
糖尿病之友
中南大学湘雅二医院 解放军第三零六医院

糖尿病之友

影响因子:0.001
ISSN:1671-3486
参考文献量15
段落导航相关论文